D A M Sloothaak1, S Sahami2, H J van der Zaag-Loonen3, E S van der Zaag4, P J Tanis2, W A Bemelman2, C J Buskens5. 1. Department of Surgery, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ Apeldoorn, The Netherlands; Department of Surgery, AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 2. Department of Surgery, AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 3. Department of Epidemiology, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ Apeldoorn, The Netherlands. 4. Department of Surgery, Gelre Hospital, Albert Schweitzerlaan 31, 7334 DZ Apeldoorn, The Netherlands. 5. Department of Surgery, AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. Electronic address: c.j.buskens@amc.uva.nl.
Abstract
INTRODUCTION: Detection of occult tumour cells in lymph nodes of patients with stage I/II colorectal cancer is associated with decreased survival. However, according to recent guidelines, occult tumour cells should be categorised in micrometastases (MMs) and isolated tumour cells (ITCs). This meta-analysis evaluates the prognostic value of MMs and of ITCs, separately. METHODS: PubMed, Embase, Biosis and the World Health Organization International Trials Registry Platform were searched for papers published until April 2013. Studies on the prognostic value of MMs and ITCs in lymph nodes of stage I/II colorectal cancer patients were included. Odds ratios (ORs) for the development of disease recurrence were calculated to analyse the predictive value of MMs and ITCs. RESULTS: From five papers, ORs for disease recurrence could be calculated for MMs and ITCs separately. In patients with colorectal cancer, disease recurrence was significantly increased in the presence of MMs in comparison with absent occult tumour cells (OR 5.63; 95%CI 2.4-13.13). This was even more pronounced in patients with colon cancer (OR 7.25 95% CI 1.82-28.97). In contrast, disease recurrence was not increased in the presence of ITCs (OR 1.00 95% CI 0.53-1.88). CONCLUSION: Patients with stage I/II colorectal cancer and MMs have a worse prognosis than patients without occult tumour cells. However, ITCs do not have a predictive value. The distinction between ITCs and MMs should be made if the detection of occult tumour cells is incorporated in the clinical decision for adjuvant treatment.
INTRODUCTION: Detection of occult tumour cells in lymph nodes of patients with stage I/II colorectal cancer is associated with decreased survival. However, according to recent guidelines, occult tumour cells should be categorised in micrometastases (MMs) and isolated tumour cells (ITCs). This meta-analysis evaluates the prognostic value of MMs and of ITCs, separately. METHODS: PubMed, Embase, Biosis and the World Health Organization International Trials Registry Platform were searched for papers published until April 2013. Studies on the prognostic value of MMs and ITCs in lymph nodes of stage I/II colorectal cancerpatients were included. Odds ratios (ORs) for the development of disease recurrence were calculated to analyse the predictive value of MMs and ITCs. RESULTS: From five papers, ORs for disease recurrence could be calculated for MMs and ITCs separately. In patients with colorectal cancer, disease recurrence was significantly increased in the presence of MMs in comparison with absent occult tumour cells (OR 5.63; 95%CI 2.4-13.13). This was even more pronounced in patients with colon cancer (OR 7.25 95% CI 1.82-28.97). In contrast, disease recurrence was not increased in the presence of ITCs (OR 1.00 95% CI 0.53-1.88). CONCLUSION:Patients with stage I/II colorectal cancer and MMs have a worse prognosis than patients without occult tumour cells. However, ITCs do not have a predictive value. The distinction between ITCs and MMs should be made if the detection of occult tumour cells is incorporated in the clinical decision for adjuvant treatment.
Authors: Elizabeth Lim; Matthew G Wiggans; Golnaz Shahtahmassebi; Somaiah Aroori; Matthew J Bowles; Christopher D Briggs; David A Stell Journal: HPB (Oxford) Date: 2016-05-20 Impact factor: 3.647
Authors: Mladjan Protic; Alexander Stojadinovic; Aviram Nissan; Zev Wainberg; Scott R Steele; David C Chen; Itzhak Avital; Anton J Bilchik Journal: J Am Coll Surg Date: 2015-05-18 Impact factor: 6.113
Authors: Wouter B Aan de Stegge; Barbara L van Leeuwen; Marloes A G Elferink; Geertruida H de Bock Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240
Authors: Luc A Heijnen; Doenja M J Lambregts; Max J Lahaye; Milou H Martens; Thiemo J A van Nijnatten; Sheng-Xiang Rao; Robert G Riedl; Jeroen Buijsen; Monique Maas; Geerard L Beets; Regina G H Beets-Tan Journal: Abdom Radiol (NY) Date: 2016-07